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Summary. A total of 62 patients with metastatic or locally 
advanced non-small -cel l  lung cancer were entered in a 
phase II study of  ACNU.  Initially, the drug was given i. v. 
at a dose of  100 mg/m 2 every 6 weeks, but due to observed 
haematological  side effects in chemotherapy-pretreated 
patients, the dose was lowered in this group to 75 mg/m 2. 
We observed one complete response in a subject exhibiting 
mult iple lung metastases and a partial response in two 
patients, one showing brain metastases and one who expe- 
r ienced local disease recurrence. The toxicity of ACNU 
mainly consisted of  bone marrow suppression especial ly 
thrombocytopenia,  with one toxic death occurring due to 
intracerebral haemorrhage. We concluded that at this dose 
and on this schedule, ACNU has l imited activity in non- 
small-cel l  lung cancer. 
Introduction 
ACNU [ 1-(4-amino-2-methyl-5-pyr imidinyl) -methyl-  (2- 
chloroethyl)-3-nitrosourea hydrochloride] is a water- and 
l ipid-soluble nitrosourea derivative developed by Arakawa 
et at. in 1974 [1]. As an alkylating agent, it shows activity 
against transplanted human xenografts of GxF1 gastric 
cancer, MX1 breast cancer and CO4 colon cancer in nude 
mice [5]. Pharmacology studies in man reveal a plasma 
half-l ife of  35 rain fol lowing intravenous administration. 
The drug is excreted via the bile and urine. 
In a phase I study performed in Japan [2], dose-l imit ing 
toxicities consisted of  granulocytopenia and thrombocyto- 
penia; other toxicities observed included nausea, vomiting, 
and anorexia. Based on the results of this phase I study, a 
dose of 100 mg/m 2 to be given at intervals of  6 -8  weeks 
was recommended. 
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The experience with ACNU in non-small -cel l  lung 
cancer is very l imited. In a phase II study performed by 
Saijo and Niitani [3], a response was observed in 5 of 
28 patients (17.9%) with squamous-cel l  carcinoma of the 
lung. To confirm these results and to augment he current 
experience with ACNU in non-small -cel l  lung cancer, the 
EORTC Lung Cancer Cooperative Group decided to per- 
form a phase II study of  ACNU in non-small -cel l  ung 
cancer. 
Patients and methods 
ACNU was given as a slow i. v. infusion at a dose of 100 mg/m 2 every 
6 weeks. Due to haematological side effects observed in chemotherapy- 
pretreated patients, the dos  was lowered uring the study to 75 mg/m 2 
every 6 weeks in this group. In cases of bone marrow suppression, 
retreatment was delayed until haematological recovery; a dose reduction 
of 25% was carried out in patients showing a WBC nadir of 1- 2 • 109/t 
and/or a platelet nadir of 50-75 x 109/1. In subjects exhibiting a WBC 
nadir of <1 x 109/1 and/or a platelet nadir of <50 x 109/1, the dose was 
reduced to 50% of the previous level. 
Patients in this study were required to have histologically proven 
non-small-cell lung cancer, locally advanced or metastastic, with mea- 
surable or evaluable lesions, documented progression within 2 months 
prior to entry into the study, an ECOG performance status of ~> 2, an age 
of <70 years, a WBC of >4x 109/1, a platelet count of >100• 109/1, a 
creatinine clearance of >40 ml/min and a serum bilirubin level of 
<2.5 mg/dl. All patients underwent a chest X-rayand, if indicated, a 
chest and/or abdominal computer-assisted tomographic (CT) scan before 
the start of treatment. During treatment, estimations of haemoglobin, 
WBC and platelets were done weekly and liver and renal functions were 
evaluated every 6 weeks. Response to treatment was assessed every 
6 weeks according to WHO criteria [7]; responses were reviewed ex- 
tramurally. 
Results 
In this phase II study, pretreated and non-pretreated 
patients were analyzed separately. A total of 62 patients 
were entered; 34 subjects had not been pretreated and 28 
had previously received various cisplatin-based chemo- 
therapy regimens. 
146 
Table 1. Patients' characteristics and treatment results 
Patients entered 62 
No previous chemotherapy 34 
Previous chemotherapy 28 
Men: Women 53 : 9 
Median age (range) 59 (41-73) years 
Median WHO performance status (range) 1 (0-2) 
Histology: 
Squamous cell carcinoma 29 
Adenocarcinoma 25 
Large-cell undifferentiated 6 
Median umber of courses given (range) 1 (1-9) 
Complete r sponse 1 
Partial response 2 
Stable disease 8 a 
Progressive disease 39 
Early death: 
Malignant disease 3 
Other causes 3 
Nonevaluable 6 
a 1 toxic death 
The patients' characteristics are summarized in Table 1. 
Overall, 50 subjects were fully evaluable for response and 
toxicity; 6 patients died before the first evaluation, sched- 
uled at 6 weeks after the first ACNU dose: 3 due to rapidly 
progressive disease and 3 due to causes not related to 
tumor or treatment. Another 6 patients were not fully 
evaluable: therapy was stopped in 1 case because of severe 
thrombocytopenia at 4 weeks after the first dose (this 
patient was included in the toxicity analysis) and in 1 
subject because of intercurrent gastro-intestinal disease; 
1 patient received an inadequate dose and 3 refused further 
treatment after the first course. 
Initially, 11 pretreated patients were started on an 
ACNU dose of 100 mg/m2; as 2 cases of grade 3 and 4 
cases of grade 4 thrombocytopenia were observed, it was 
decided to lower the ACNU dose to 75 rag/m2 in this 
patient group. We observed a complete response in 
1 patient with multiple lung metastases from an adeno- 
carcinoma, which lasted for 9 months, and 2 partial re- 
sponses: 1 in a local recurrence of an adenocarcinoma (for 
a duration of 9 months) and 1 in brain metastases from a 
squamous-cell carcinoma that lasted for 2 months. Two 
patients had not previously been treated; the response in 
the local recurrence occurred in a previously heavily pro- 
treated subject who was treated at a dose of 75 mg/m 2. The 
overall response rate was 5% (95% confidence limits, 
1.7%-22.4%). 
The observed toxicity consisted mainly of bone manow 
depression, including granulocytopenia of grades 3 (four 
cases) and 4 (one patient) and thrombocytopenia of grades 
3 (seven subjects) and 4 (eight cases). Seven patients re- 
quired platelet ransfusions. One toxic death occurred ue 
to an intracerebral haemorrhage during grade 4 thrombocy- 
topenia. After lowering the ACNU dose in pretreated sub- 
jects we observed only 1 case of grade 3 and 1 of grade 4 
thrombocytopenia in 14 patients. In the non-pretreated 
patients, four cases of grade 3 and three of grade 4 throm- 
bocytopenia were observed, in one patient during the first 
course and in the others during the second and third 
courses. WBC nadirs occurred at week 4 and platelet 
nadirs, at week 5, causing treatment delays in five courses. 
Other toxicities observed were nausea nd vomiting (grade 
3 in 4 patients) and alopecia (grade 1 in 12 subjects). 
Discussion 
Prior to the cisplatin era, nitrosourea derivatives were 
frequently incorporated in chemotherapy regimens for 
non-small-cell lung cancer. CCNU and methyl-CCNU 
show some activity as single agents [6] but have the dis- 
advantage of being lipid-soluble and must therefore be 
given by mouth. ACNU is lipid- and water-soluble and can 
be safely given intravenously. Apart from bone marrow 
toxicity, ACNU produces only minor gastrointestinal side 
effects; it lacks nephrotoxicity and pulmonary toxicity, in 
contrast o methyl-CCNU and BCNU. Because of these 
characteristics and the response rate of 17.8% previously 
observed in squamous-cell lung cancer [3], our group con- 
sidered it worthwhile to study ACNU in all histological 
subtypes of lung cancer. On the schedule used in the pre- 
sent study, we could not verify the results obtained by Saijo 
and Niitani [3]; we observed 1 complete and 2 partial 
responses in 50 evaluable patients. Using a slightly lower 
dose, Sasaki et al. [4] observed no responders among 
21 patients. The better esults of Saijo and Niitani [3] can- 
not be explained by selection of histology. In our study, 
only 1 of 29 patients with squamous-cell carcinoma re- 
sponded. The ACNU toxicity observed in this study con- 
sisted mainly of thrombocytopenia and tended to increase 
with continuation of treatment. We conclude that the activ- 
ity of ACNU in non-small-cell lung cancer is negligible at 
this dose and on this schedule. 
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